FDA panel endorses first-of-a-kind cancer blood test from Grail
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA panel endorses first-of-a-kind cancer blood test from Grail" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The New York Times and WSJ. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 16h ago.
Quick answers
Why is "FDA panel endorses first-of-a-kind cancer blood test from Grail" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- FDA panel endorses first-of-a-kind cancer blood test KCCI · 6h ago
- US FDA advisers endorse Grail cancer test's benefits in key vote Reuters · 16h ago
- FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test prnewswire.com · 17h ago
- FDA advisory panel endorses controversial cancer blood test The Seattle Times · 17h ago
- Cancer-screen blood test wins tepid support from US drug advisory panel ft.com · 17h ago
- Blood test for multiple cancers clears crucial hurdle on track to FDA approval Scientific American · 17h ago
- F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test The New York Times · 17h ago
- Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval WSJ · 17h ago
Topics
Related trends
Meta Brings FDA-Cleared Hearing Enhancement To Its Smart Glasses
Meta is introducing FDA-cleared hearing enhancement features to its smart glasses, joining Apple in the wearable health space.
Holy Grail Of Rocketry
4 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Check your freezer: Popular Walmart item recalled over possible listeria risk
A nationwide food safety alert impacts popular frozen pasta sold at Walmart due to potential listeria contamination.
These discreet hearing aid glasses now have better voice boosting and battery life
EssilorLuxottica launches next-gen Nuance Audio Plus smart glasses following FDA clearance.